Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus
Abhibroto Karmakar,Uma Kumar,Smitha Prabhu,Vinod Ravindran,Shankar Prasad Nagaraju,Varashree Bolar Suryakanth,Mukhyaprana M. Prabhu,Subhradip Karmakar
DOI: https://doi.org/10.1007/s10238-024-01484-z
IF: 4.6
2024-09-20
Clinical and Experimental Medicine
Abstract:Systemic lupus erythematosus (SLE) is a chronic, heterogeneous, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. SLE predominantly affects young, middle-aged, and child-bearing women with episodes of flare-up and remission, although it affects males at a much lower frequency (female: male; 7:1 to 15:1). Technological and molecular advancements have helped in patient stratification and improved patient prognosis, morbidity, and treatment regimens overall, impacting quality of life. Despite several attempts to comprehend the pathogenesis of SLE, knowledge about the precise molecular mechanisms underlying this disease is still lacking. The current treatment options for SLE are pragmatic and aim to develop composite biomarkers for daily practice, which necessitates the robust development of novel treatment strategies and drugs targeting specific responsive pathways. In this communication, we review and aim to explore emerging therapeutic modalities, including multiomics-based approaches, rational drug design, and CAR-T-cell-based immunotherapy, for the management of SLE.
medicine, research & experimental